Mio-Rel en es it fr

Mio-Rel Brand names, Mio-Rel Analogs

Mio-Rel Brand Names Mixture

  • No information avaliable

Mio-Rel Chemical_Formula


Mio-Rel RX_link


Mio-Rel fda sheet

Mio-Rel FDA

Mio-Rel msds (material safety sheet)

Mio-Rel MSDS

Mio-Rel Synthesis Reference

No information avaliable

Mio-Rel Molecular Weight

269.381 g/mol

Mio-Rel Melting Point

156-157 oC

Mio-Rel H2O Solubility

Sparingly soluble in water

Mio-Rel State


Mio-Rel LogP


Mio-Rel Dosage Forms

Tablet (extended-release)

Mio-Rel Indication

Indicated for the treatment of Parkinson's disease.

Mio-Rel Pharmacology

Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.

Mio-Rel Absorption

Orphenadrine is almost completely absorbed in the gastrointestinal tract.

Mio-Rel side effects and Toxicity

Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg

Mio-Rel Patient Information

No information avaliable

Mio-Rel Organisms Affected

Humans and other mammals